Development of a new class of bacterial resistance inhibitors for the treatment of multi-drug resistant infection

多药耐药(MDR)的传播有可能改变全球医疗保健的面貌，使依赖于控制免疫系统薄弱患者感染的能力的医院单位陷入瘫痪。除非我们能开发出解决细菌耐药性的新方法，否则我们有可能回到“抗生素出现前”的时代。蓝莓治疗公司旨在评估一种创新的治疗方法的可行性，该方法使用一种新的纳米颗粒递送系统配制的多肽适配子来抑制MDR的关键机制。通过直接针对耐药机制，我们希望逆转细菌的耐药性，并使耐药细菌再次对现有的常用抗生素敏感。我们的目标是证明这种方法在临床相关的多药耐药细菌物种中恢复抗生素敏感性的可行性，如果成功，将是开发治疗多药耐药感染的新疗法的第一步。

The spread of multi-drug resistance (MDR) threatens to change the face of health care worldwide, crippling hospital units that rely on the ability to control infections in patients with weakened immune systems. We risk returning to a "pre-antibiotic" era unless we can develop new approaches to tackling bacterial resistance. Blueberry Therapeutics aims to assess the feasibility of an innovative therapeutic approach to inhibit key mechanisms of MDR using peptide aptamers formulated with a new nanoparticle delivery system. By directly targeting the mechanisms of resistance we hope to reverse bacterial resistance and render drug resistant bacteria sensitive to treatment with already available and common antibiotics again. We aim to demonstrate the feasibility of this approach to restore antibiotic sensitivity in clinically relevant MDR bacterial species and if successful will be the first step in developing a new class of therapies with which to treat MDR infections.